A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

June 23, 2024

Study Completion Date

June 23, 2024

Conditions

Healthy

Interventions

DRUG

MK-8507

Oral administration

DRUG

Islatravir

Oral administration

Trial Locations (1)

Celerion (Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06619678 - A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016) | Biotech Hunter | Biotech Hunter